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Predicting prostate cancer-speciﬁc outcome after radical
prostatectomy among men with very high-risk cT3b/4 PCa:
a multi-institutional outcome study of 266 patients
F Moltzahn1, J Karnes2, P Gontero3, B Kneitz4, B Tombal5, P Bader6, A Briganti7, F Montorsi7, H Van Poppel8, S Joniau8 and M Spahn1
BACKGROUND: The value of radical prostatectomy (RP) as an approach for very high-risk prostate cancer (PCa) patients is
controversial. To examine the risk of 10-year cancer-speciﬁc mortality (CSM) and other-cause mortality (OCM) according to
clinical and pathological characteristics of very high-risk cT3b/4 PCa patients treated with RP as the primary treatment option.
METHODS: In a multi-institutional cohort, 266 patients with very high-risk cT3b/4 PCa treated with RP were identiﬁed. All patients
underwent RP and pelvic lymph-node dissection. Competing-risk analyses assessed 10-year CSM and OCM before and after
stratiﬁcation for age and Charlson comorbidity index (CCI).
RESULTS: Overall, 34 (13%) patients died from PCa and 73 (28%) from OCM. Ten-year CSM and OCM rates ranged from 5.6% to
12.9% and from 10% to 38%, respectively. OCM was the leading cause of death in all subgroups. Age and comorbidities were the
main determinants of OCM. In healthy men, CSM rate did not differ among age groups (10-year CSM rate for ⩽ 64, 65–69 and ⩾ 70
years: 16.2%, 11.5% and 17.1%, respectively). Men with a CCI ⩾ 1 showed a very low risk of CSM irrespective of age (10-year CSM:
5.6–6.1%), whereas the 10-year OCM rates increased with age up to 38% in men ⩾ 70 years.
CONCLUSION: Very high-risk cT3b/4 PCa represents a heterogeneous group. We revealed overall low CSM rates despite the highly
unfavorable clinical disease. For healthy men, CSM was independent of age, supporting RP even for older men. Conversely, less
healthy patients had the highest risk of dying from OCM while sharing very low risk of CSM, indicating that this group might not
beneﬁt from an aggressive surgical treatment. Outcome after RP as the primary treatment option in cT3b/4 PCa patients is related
to age and comorbidity status.
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INTRODUCTION
The majority of patients with newly diagnosed prostate cancer
(PCa) are at low risk for disease progression; however, up to 25%
present with unfavorable tumor characteristics (PSA420 ngml− 1,
cT3/4 or biopsy Gleason score (GS) 8–10) and are therefore
stratiﬁed as high-risk patients.1 These men have a signiﬁcant risk
of disease progression and cancer-related death when left
untreated.2 However, the optimal treatment of these patients is
unclear and intensively debated. The treatment approaches vary
within the high-risk group, and treatment trends suggest that at
least some men with high-risk localized disease are treated with
androgen deprivation therapy (ADT) alone, which in that setting
does not extend survival.3 Radiation therapy combined with ADT
for 18 months to 3 years is considered standard of care for high-
risk patients.2 Interestingly, excellent outcomes have been
recently reported for surgically treated patients.4 However, for
men with very high-risk PCa, surgery is only an optional treatment
in case the tumor is not ﬁxed to the pelvic wall and does not
inﬁltrate the urethral sphincter, as the goal of the radical
prostatectomy (RP) is to remove the cancer completely to achieve
local tumor control.2 Surgical complications are not very well
documented for this patient group. A recent study compared
results after RP in very high-risk PCa patients with those having
localized PCa and found no differences for surgical morbidity
between the two groups except for operative time, blood
transfusion and lymphoceles, which showed a higher rate in
patients with locally advanced disease.5
According to oncological outcome, excellent 7- and 10-year
cancer-speciﬁc survival (CSS) rates of 90% and 88% were reported
in two smaller single center series, respectively;5,6 however, the
overall survival rate was reported in 76.7% and 71% at 7 and
10 years, respectively.
Importantly, the balance of beneﬁts (e.g. reduction of cancer-
speciﬁc mortality (CSM)) and side effects of each therapy modality
must be considered with regard to the patient's individual
circumstances (e.g. age, comorbidities). For radical surgery, we
and others demonstrated that age and comorbidities are relevant
factors that inﬂuence non-cancer mortality in high-risk PCa
patients.7,8 Interestingly, CSM was modest in surgically treated
high-risk PCa patients and represented the leading cause of death
only in young, healthy patients. Conversely, older and less healthy
patients with multiple risk factors were those at the highest risk of
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dying from other-cause mortality (OCM) while sharing very low
CSM rates.7
The aim of this study was to analyze the 10-year CSM and
OCM rates according to the clinical and pathological charac-
teristics of surgically treated very high-risk cT3b/4 PCa patients.
MATERIALS AND METHODS
In total, 266 men with clinical stage cT3b/4 PCa were retro-
spectively identiﬁed in our multi-institutional database from 1988
to 2010 in seven tertiary care centers. Clinical staging was based
on digital rectal examination. All patients had negative bone
scans; the clinical node-positive disease in the pelvic area was not
considered an exclusion criteria. Decision and timing of adjuvant
treatments such as ADT and/or radiotherapy were made accord-
ing to the individual institutional protocols of the institutions.
Patients were ﬁrst stratiﬁed to clinically relevant age groups (⩽64,
65–69 and ⩾ 70 years) and thereafter according to their general
health status, as assessed by the Charlson comorbidity index (CCI
cutoff was arbitrarily set to 0 vs ⩾ 1). Tumor characteristics
included clinical stage (cT3b/cT4), preoperative PSA, biopsy and
ﬁnal GS (⩽6, 7 or 8–10), the number of risk factors, pathological
stage and lymph-node status (lymph-node negative (N− ) or
node-positive (N+)). Physician correspondence and/or death
certiﬁcations allowed us to deﬁne CSM (coded as death from
PCa) and OCM (death from all other events). All analyses were
conducted using R version 2.12.1 (R Development Core Team,
Vienna, Austria) and all P-values were related to two-sided test
with an α-level of 0.05. The χ2 test was used to compare
proportions. Fisher’s exact test was used to ﬁnd whether
categorized age is related to other patients’ characteristics.
To compare the cumulative incidence function of CSM and
OCM between different age groups under the consideration of
competing risks, the Gray’s test was performed. Taking competing
risks into account, univariate and multivariate models were ﬁtted
by using Fine and Gray’s model, to ﬁnd the predictors of time to
CSM and OCM. Additionally, the cumulative incidence functions
with corresponding 10-year rates of OCM and CSM stratiﬁed by
age groups and CCI status were estimated.
RESULTS
The mean age at the time of surgery was 65 years. Overall, 178
patients (66.9%) had no comorbidities (CCI = 0) and 64.2% of all
patients had only one high-risk factor (cT3b/4) at diagnosis. The
vast majority were cT3b tumors (90.6%). Following stratiﬁcation
according to age groups, 42.5%, 33.1% and 24.4% were age ⩽ 64,
65–69 and ⩾ 70 years. With increasing age, patients were more
likely to have comorbidities (CCI⩾ 1, P⩽ 0.03) and more than one
high-risk factor (PSA420, GS 8–10, P⩽ 0.02) (Table 1). Of the 266
patients, 104 (40%) were overstaged and showed pT2 (n= 50) or
pT3a (n= 54) tumors in the ﬁnal histopathology. Overall, 152
patients (57.1%) had positive surgical margins and 30 (11.2%) had
positive lymph nodes, respectively. Adjuvant treatment was
administered to 130 patients (48.8%) (Table 1). After a median
follow-up of 111 months, 107 patients (40.3%) died; of these, 34
patients (31.7%) died because of CSM, whereas 73 (68.3%)
because of OCM.
Using univariate analyses, we showed that higher numbers of
comorbidities (CCI⩾ 1 vs CCI = 0; hazard ratio (HR): 0.33; P: 0.032)
reduced the risk of CSM, whereas higher numbers of high-risk
factors (HR of 2–3 vs 1: 2.13; P: 0.024), higher clinical stage (HR of
cT4 vs cT3b: 5.23; P: ⩽ 0.0001) and higher biopsy GSs (HR of
GS 8–10 vs ⩽ 6 = 2.43; P: 0.03) increased the risk of CSM (Table 2).
However, only increased comorbidities reduced and higher clinical
stage increased CSM using multivariate analyses, while biopsy GS,
number of risk factors and adjuvant treatment were not
statistically signiﬁcant (Table 2). Conversely, age was signiﬁcantly
associated with OCM in both uni- and multivariate analyses
(Table 2). Gleason sum (HR of 8–10 vs ⩽ 6 = 5.6; P: 0.0022) and
positive surgical margins (HR of positive vs negative 4.8; P: 0.03)
were also independent predictors of CSM; however, these are
postoperative risk factors as they were not relevant for treatment
decision (Table 3). The overall 10-year CSS rate was 86.5% (95%
conﬁdence interval: 81.7–91.5%). When patients were classiﬁed
according to age only, CSM rates for younger patients (⩽64 years)
reached 12.89% at 10 years. In this group, CSM and OCM rates did
not differ signiﬁcantly (12.89% vs 13.49%, respectively). Similarly,
even among older patients CSM had a comparable impact on
patient survival (10.59% and 12.74% for patients age 65–69 and
⩾ 70 years, respectively). However, OCM, and not CSM, was the
leading cause of death in these age groups (21.72% and 34.93% vs
10.59% and 12.74%), respectively (Figure 1).
When patients were further subdivided according to age and
comorbidities, the CSM rates for healthy men (CCI = 0) were
comparable for all age groups with an estimated 10-year CSM rate
of 16.2%, 11.5% and 17.1% for the age groups (⩽64, 65–69 and
⩾ 70 years), respectively. Conversely, the CSM rate was much
lower in men with CCI⩾ 1 with an estimated 10-year CSM rate of
5.6–6% for all age groups (Figure 2). As expected, the OCM rate
invariably rose with increasing age and comorbidities with an
estimated 10-year rate of 14.3% vs 18.4% vs 34.7% for CCI = 0 and
10.1% vs 34.4% vs 37.9% for CCI ⩾ 1 for patients age (⩽64, 65–69
and ⩾ 70 years), respectively (Figure 2).
DISCUSSION
We assessed the outcome of 266 men with very high-risk cT3b/4
PCa treated with RP alone or in combination with adjuvant
therapies at seven tertiary referral centers. We found that clinical,
very high-risk PCa represents a heterogeneous group of patients
not only in terms of staging (40% pT2) but also in terms of
outcome. After stratiﬁcation of patients for age and CCI, we found
that even in this very high-risk PCa patients OCM represented the
leading cause of death in all subgroups (P= 0.001). CSM was
relevant in patients without comorbidities of all age groups
(P= 0.034). First, we conﬁrmed previous reports from smaller
single center series demonstrating excellent long-term outcome in
surgically treated very high-risk PCa patients with an estimated
10-year CSS rates of 86.5% for the entire cohort.5,6 CSM rates were
highest in healthy men. In these men, the effect of age on CSM
was minimal and the 10-year CSM rates ranged from 11.5% to
17.1%. Conversely, CSM rates were as low as 6% in men with
comorbidities of all age groups. These results also conﬁrm
previous reports on heterogeneous outcomes in high-risk PCa
patients.9–12 Second, even in this very high-risk cohort OCM
was the leading cause of death (P= 0.001). Increasing age
and comorbidities were associated with increasing OCM rates.
Especially men aged 465 years with comorbidities had higher
10-year OCM rates (38%) when compared with their healthy
counterparts (18%). Our data are of considerable clinical
importance. Very high-risk PCa patients are usually treated
aggressively and the main challenge is to achieve local tumor
control as well as to treat any microscopic metastases.2 Provided
the tumor is not ﬁxed to the pelvic wall, or there is no invasion to
the urethral sphincter, RP is recommended as one reasonable
treatment option in selected patients with very high-risk PCa.
Recent studies showed overall survival and CSS rates of up to
76.7% and 90.2%, respectively.5,6 However, there is a considerable
fear to leave these patients undertreated. Our data are from
different institutions and reﬂects this problem with 49% of the
patients receiving any kind of adjuvant treatment. A multi-
disciplinary treatment decision should balance the beneﬁts and
side effects of all treatment modalities and consider individual
patient circumstances. Life expectancy is a major determinant of
the potential beneﬁt from treatment and is mainly affected by
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patient’s age and comorbidities. Our results demonstrate that age
alone does not affect the cancer outcome of healthy patients. The
long-term CSM of older men (⩾70 years) is comparable to younger
patients (⩽64 years). These data support RP even for older,
but healthy patients. However, the leading cause of death in men
⩾ 70 years was non-tumor related and the difference between
OCM and CSM was 17% at 10 years. A systematic evaluation of
dependence and nutritional status might be helpful to further
support the indication for RP in these otherwise healthy patients.13
Conversely, the impact of CSM on the survival of less healthy
men (CCI ⩾ 1) of all age groups was low (10-year CSM rate o6%)
and the difference between OCM and CSM was higher in these
patients (34.4% and 37.9% for age groups 65–69 and 470 years,
respectively). Interestingly, CSM and OCM was much lower in unﬁt
younger (⩽64 years) patients (10-year CSM and OCM rates ranged
from 6% to 10.1%, respectively) when compared with their healthy
counterparts. This effect might be caused by the small sample size
in this subgroup.
Based on these ﬁndings, even in the absence of comparative
data from conservatively managed patients, it is likely that
especially older, morbid patients might not beneﬁt from an
aggressive treatment because of the high risk of dying from
OCM.8,14–16 Several studies have addressed the impact of age
and comorbidities on CSM and OCM rates in different risk
groups,4,14,17,18 but none of them focused on surgically treated
very high-risk cT3b/4 PCa patients. Albertsen et al.14 reported on a
Table 1. Patient characteristics
Variable Overall (N=266) ⩽ 64 years (n=113) 65–69 years (n=88) ⩾ 70 years (n= 65) P-value
Mean age (years) 65 58 67 73
CCI
0 178 80 (77.7%) 58 (70.7%) 40 (65.6%) 0.21
⩾ 1 68 23 (22.3%) 24 (29.3%) 21 (34.4%)
NA 20 10 (3.8%) 6 (2.3%) 4 (1.5%)
Number of risk factors
1 166 80 (70.8%) 53 (60.2%) 33 (50.8%) 0.02
2–3 100 33 (29.2%) 35 (39.8%) 32 (49.2%)
Clinical stage
cT3b 241 106 (93.8%) 77 (87.5%) 58 (89.2%) 0.25
cT4 25 7 (6.2%) 11 (12.5%) 7 (10.8%)
Biopsy Gleason score
⩽ 6 100 43 (38.1%) 36 (40.9%) 21 (32.3%) 0.01
7 98 50 (44.2%) 31 (35.2%) 17 (26.2%)
8–10 68 20 (17.7%) 21 (23.9%) 27 (41.5%)
PSA preoperative 20 21 22 17 0.88
Final Gleason score
⩽ 6 69 32 (29.1%) 21 (24.1%) 16 (24.6%) 0.67
7 111 43 (39.1%) 42 (48.3%) 26 (40.0%)
8–10 82 35 (31.8%) 24 (27.6%) 23 (35.4%)
NA 4 3 (1.1%) 1 (0.4%) 0 (0.0%)
Pathological stage
pT2 50 22 (19.5%) 20 (22.7%) 8 (12.3%) 0.46
pT3a 54 25 (22.1%) 16 (18.2%) 13 (20.0%)
pT3b 111 48 (42.5%) 36 (40.9%) 27 (41.5%)
pT4 21 7 (6.2%) 9 (10.2%) 5 (7.7%)
N+ 30 11 (9.7%) 7 (8.0%) 12 (18.5%)
Surgical margin status
Negative 114 43 (38.1%) 45 (51.1%) 26 (40.0%) 0.15
Positive 152 70 (61.9%) 43 (48.9%) 39 (60.0%)
Adjuvant treatment
No 136 60 (53.1%) 43 (48.9%) 33 (50.8%) 0.83
Yes 130 53 (46.9%) 45 (51.1%) 32 (49.2%)
Adjuvant RT
No 221 93 (82.3%) 71 (80.7%) 57 (87.7%) 0.49
Yes 45 20 (17.7%) 17 (19.3%) 8 (12.3%)
Adjuvant ADT
No 160 68 (60.2%) 55 (62.5%) 37 (56.9%) 0.78
Yes 106 45 (39.8%) 33 (37.5%) 28 (43.1%)
Adjv. ADT and RT 21 12 (10.6%) 5 (5.6%) 4 (6.1%) 0.32
Abbreviations: ADT, androgen deprivation therapy; CCI, Charlson comorbidity index; RT, radiotherapy.
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large cohort of conservatively treated patients with localized PCa
and stratiﬁed for age and comorbidities but did not stratify for
high-risk factors. Daskivich et al.15 reported on 2366 men receiving
aggressive treatment, but only 137 (4.3%) were affected by cT3
tumors. In addition, the study was limited by the lack of any
stratiﬁcation of the very high-risk patients according to age,
comorbidities and treatment modality. Finally, even though a
retrospective comparison might be inappropriate, our long-term
CSM rates are signiﬁcantly lower compared with those from a
large population-based study of men with locally advanced PCa
treated with non-curative intent.8 In contrast to our results, PCa
was the leading cause of mortality in all patient subgroups with
10-year CSM rates of up to 52%. These differences have to be
interpreted with care because selection bias might have affected
the results. However, it is obvious that especially older patients
with comorbidities might not beneﬁt from radical treatment
because the OCM overexceed CSM by several folds. Our study is
lacking control data from patients receiving no therapy; however,
it is still worth to be set in relation to data from such patients of
previous studies with all known limitations in terms of methodo-
logy and patient selection: EORTC trial 30891 compared immedi-
ate endocrine treatment vs deferred hormonal treatment at the
time point of systemic progression in men newly diagnosed with
T0-4 N0-2 M0 PCa who refused local treatment or were considered
Table 2. Univariable and multivariable competing-risk analyses predicting cancer-speciﬁc mortality and other-cause mortalitya
Variables Cancer-speciﬁc mortality Other-cause mortality
Univariable HR P-value Multivariable HR P-value Univariable HR P-value Multivariable HR P-value
Age at surgery (years)
65–69 vs o64 0.97 (0.45–2.1) 0.95 0.67 (0.29–1.55) 0.35 1.65 (0.94–2.9) 0.084 1.77 (1–3.15) 0.052
⩾ 70 vs o64 0.89 (0.38–2.09) 0.78 0.62 (0.24–1.58) 0.31 2.68 (1.53–4.66) 0.0005 2.94 (1.6–5.42) 0.0005
CCI
⩾ 1 vs 0 0.33 (0.12–0.91) 0.032 0.26 (0.08–0.83) 0.023 1.31 (0.81–2.13) 0.27 1.25 (0.77–2.03) 0.36
Clinical stage
cT4 vs cT3b 5.23 (2.37–11.54) o0.0001 11.86 (2.92–48.08) 0.005 0.87 (0.34–2.25) 0.77 0.58 (0.2–1.64) 0.3
Preop. PSA value 1 (1–1) 0.72 0.99 (0.98–1) 0.21 1 (1–1.01) 0.043 1.01 (1–1.01) 0.0001
Biopsy Gleason sum
7 vs ⩽ 6 1.14 (0.49–2.66) 0.76 1.06 (0.43–2.62) 0.90 0.74 (0.43–1.27) 0.27 0.71 (0.39–1.29) 0.26
8–10 vs ⩽ 6 2.43 (1.09–5.41) 0.03 3.97 (0.71–22.36) 0.12 0.89 (0.5–1.59) 0.70 0.85 (0.28–2.56) 0.77
No. of risk factors
2–3 vs 1 2.13 (1.11–4.1) 0.024 0.62 (0.1–3.86) 0.61 0.95 (0.58–1.56) 0.83 0.76 (0.3–1.91) 0.56
Abbreviations: CCI, Charlson comorbidity index; HR, hazard ratio. aIn patients treated with radical prostatectomy for very high-risk prostate cancer according to
preoperative variables.
Table 3. Univariable and multivariable competing-risk analyses predicting cancer-speciﬁc mortality and other-cause mortalitya
Variables Cancer-speciﬁc mortality Other -cause mortality
Univariable HR P-value Multivariable HR P-value Univariable HR P-value Multivariable HR P-value
Age at surgery (years)
65–69 vs o64 0.97 (0.45–2.1) 0.95 1.08 (0.46–2.5) 0.86 1.6 (0.94–2.9) 0.084 1.69 (0.92–3.11) 0.093
⩾ 70 vs o64 0.89 (0.38–2.09) 0.78 1.02 (0.41–2.56) 0.97 2.68 (1.53–4.66) 0.0005 2.71 (1.56–4.72) 0.0004
CCI
⩾ 1 vs 0 0.33 (0.12–0.91) 0.032 0.27 (0.09–0.83) 0.023 1.31 (0.81–2.13) 0.27 1.33 (0.82–2.14) 0.25
Final Gleason sum
7 vs ⩽ 6 1.18 (0.35–4.03) 0.79 2.1 (1.46–4.14) 0.021 0.55 (0.57–1.12) 0.34 0.66 (0.51–1.67) 0.51
8–10 vs ⩽ 6 8.04 (2.73–23.67) 0.0002 0.97 (0.3–3.19) 0.96 0.92 (0.56–1.52) 0.75 0.78 (0.46–1.31) 0.35
Surgical margin status
Pos vs neg 7.86 (2.42–25.59) 0.0006 5.6 (1.85–16.9) 0.0022 0.76 (0.4–1.43) 0.39 0.71 (0.38–1.36) 0.3
LN status
N+ vs N− 5.1 (2.01–7.44) 0.012 4.8 (1.16–19.8) 0.03 0.72 (0.46–1.12) 0.15 0.89 (0.53–1.48) 0.64
Adjuvant therapies
Yes vs no 4.4 (1.94–9.94) 0.72 1.1 (0.37–3.28) 0.87 0.65 (0.41–1.04) 0.074 0.79 (0.46–1.36) 0.4
Abbreviations: CCI, Charlson comorbidity index; HR, hazard ratio; LN, lymph node. aIn patients treated with radical prostatectomy for very high-risk prostate
cancer according to postoperative variables.
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ineligible because of a limited life expectancy or severe
comorbidities.16 Recently, the group released the results after a
median of 12.8 years.19 Out of 985 patients, 78% died, including
27% from PCa. Interestingly, time to objective castration-resistant
disease after deferred ADT did not differ signiﬁcantly (P= 0.42)
from that after immediate ADT. In addition, PCa mortality did
not differ signiﬁcantly, except in patients with aggressive PCa,
that is, those with a baseline PSA 450 ng/ml or a PSA doubling
time o12 months, resulting in death within 3–5 years after
diagnosis.
Patients having N+ disease are also classiﬁed to be at very high
risk as N+ disease will mostly be followed by systemic disease
progression, and all patients with signiﬁcant N+ disease ultimately
fail treatment.20 The diagnosis of positive LNs during lymph-node
dissection may potentially lead to the abandonment of RP.
However, a recent analysis by Engel et al.21 compared the overall
and relative survival rates in N+ patients with or without
abandoned RP and revealed that N+ patients with complete RP
had improved survival compared with patients with abandoned
RP.20 Similarly, results were corroborated in a contemporary
retrospective series in men, found to have nodal metastasis, by
intraoperative frozen sections. Completion of RP was an inde-
pendent predictor of improved CSS in the multivariate analysis.22
The combination of RP and early adjuvant HT in pN+ PCa has
been shown to achieve a 10-year CSS rate of 80%.20 However,
in our cohort, only a minority of patients had N+ disease, and
therefore we cannot provide the statistical outcome data for
this group.
Despite its validity, the retrospective nature of our study and a
selection toward more healthy men with more favorable tumor
characteristics might have biased our results. The inclusion of only
a limited number of patients with high CCI scores did not allow us
to test for less favorable comorbidity proﬁles. In addition, all
patients were deemed suitable to undergo RP and therefore
might be healthier as compared with their conservatively treated
counterparts. The impact of CCI on OCM might have been
underestimated in our series. The higher number of high-risk
factors with increasing age might have caused an overestimation
of CSM rates when comparing age groups. On the other hand, the
high number of pathological T2 tumors might lead to an
overestimation of other competing causes of death. No central
pathology review was performed; however, all patients were
treated at high-volume tertiary referral centers with dedicated
uropathologists. Another limitation is the management of
adjuvant therapies according to different institutional protocols
as they itself usually depend on age and comorbidities. We here
analyze the largest so far published cohort of men treated with RP
for very high-risk PCa; however, categorization into different age
groups may have let the analysis underpowered to assess this
outcome.
No data on postoperative quality of life were available. Our
10-year follow-up could limit our conclusions, as, from the
Swedish registry, it is known that a difference in survival is found
Age 
group
10yr. CSM rates 10yr. OCM 
rates
≤64 12.89% 13.49%
65-69 10.59% 21.72%
≥70 12.74% 34.93%
p-value 0.95 0.001
Figure 1. Cumulative incidence function of other-cause mortality (OCM) and cancer-speciﬁc mortality (CSM) stratiﬁed by age.
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not before 15 years of follow-up. Moreover, the ascertainment of
cause of death using physician correspondence and/or death
certiﬁcations potentially harbors a limitation of this study. Finally,
it is possible that through the time span of the study signiﬁcant
changes in the surgical approach and postoperative management
of high-risk PCa have occurred and clinical staging is more
accurate nowadays by using multiparametric MRI.
Despite these limitations, we believe our study represents the
ﬁrst analysis focusing on the long-term survival of surgically
treated very high-risk patients using a competing-risk approach.
CONCLUSION
The results of our study demonstrated the heterogeneity of
very high-risk PCa in terms of staging and outcome. Overall, we
revealed low CSM rates despite the highly unfavorable clinical
disease status. After stratiﬁcation for age and comorbidity proﬁle
in men treated with RP for very high-risk PCa, we found that even
in this cohort OCM represented the leading cause of death in all
patient subgroups. Especially for healthy men, the risk of dying
from PCa was independent of age, suggesting a role for RP as a
primary option even for older, but otherwise healthy men.
Conversely, less healthy patients were those with the highest risk
of dying from OCM while sharing very low risk of dying from PCa,
indicating that this group might not beneﬁt from an aggressive
surgical treatment.
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Figure 2. Competing-risks models depicting cancer-speciﬁc mortality (CSM) and other-cause mortality (OCM) survival curves up to 10 years
(n= 266) stratiﬁed according to age group and comorbidity status assessed by the Charlson comorbidity index (CCI) score. HR, hazard ratio.
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